MaxCyte, Inc. Deferred Costs, Noncurrent
MaxCyte, Inc. (MXCT) had Deferred Costs, Noncurrent of $0 as of 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredCosts · last filed 2023-03-15
- 2022-12-31: Deferred Costs, Noncurrent $0.00.
- 2021-12-31: Deferred Costs, Noncurrent $0.00.
- 2021-09-30: Deferred Costs, Noncurrent $0.00.
- 2021-06-30: Deferred Costs, Noncurrent $1.38M.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.38M 10-Q · filed 2021-09-13 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |